Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 2:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 79,372 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 2 Clear all

Conditions: Parkinson's Disease
Interventions: ABBV-0805, Placebo ABBV-0805; Drug
Lead sponsor: AbbVie; Industry
Eligibility: Up to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 5
States / cities: Gainesville, Florida • New York, New York • Durham, North Carolina + 2 more

Conditions: Breast Cancer
Interventions: multiple beams utilizing either intensity-modulated or 3D-conformal techniques; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more

Conditions: Personal Satisfaction
Interventions: Hyaluronic acid filler injection; Procedure
Lead sponsor: Marmur Medical; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Glioblastoma, Cancer of Brain and Nervous System, Glioblastoma Multiforme
Interventions: Temozolomide, Stereotactic Radiosurgery (SRS); Drug · Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 1
States / cities: Stanford, California

Conditions: Concussion, Brain
Interventions: Not listed
Lead sponsor: ElMindA Ltd; Industry
Eligibility: 12 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Brighton, Michigan

Conditions: HIV
Interventions: Monetary Incentive, Questionnaire Timing, HIV Test Offering; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 13 Years to 64 Years
Enrollment: 8,572 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Psychosis, Schizophrenia, Schizo Affective Disorder
Interventions: Transcranial alternating current stimulation; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 64 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy Participants Study
Interventions: N,N-Dimethyltryptamine (15 mg), N,N-Dimethyltryptamine (17.5 mg); Drug
Lead sponsor: Jon Dean; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Gastric Cancer
Interventions: questionnaires; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 971 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2024
U.S. locations: 9
States / cities: Los Angeles, California • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: Peripheral Arterial Disease, Claudication (Finding)
Interventions: Cilostazol; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 35 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Menopause
Interventions: ERr 731 - Micro-coated, ERr 731 - Enteric coated; Dietary Supplement
Lead sponsor: Metagenics, Inc.; Industry
Eligibility: 35 Years to 64 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Gig Harbor, Washington

Conditions: Duchenne Muscular Dystrophy
Interventions: Ataluren; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 2 Years to 5 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 6
States / cities: Gulf Breeze, Florida • Chicago, Illinois • Boston, Massachusetts + 3 more

Conditions: Arthroplasty, Replacement, Hip
Interventions: Testosterone Therapy, No Testosterone Therapy; Drug · Other
Lead sponsor: American Hip Institute; Other
Eligibility: 50 Years and older · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Des Plaines, Illinois

Conditions: Cancer, Obesity, Lifestyle, Sedentary, Physical Activity, Health Behavior, Chronic Disease, Diet Modification
Interventions: Community Garden Intervention; Behavioral
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 18 Years and older
Enrollment: 296 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Type 2 Diabetes
Interventions: Byetta (exenatide), Symlin (pramlintide); Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 12 Years to 21 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: YouTHrive, Information-only Control; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 15 Years to 24 Years
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 7
States / cities: Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 4 more

Conditions: Otitis Media in Patients With Tympanostomy Tubes
Interventions: Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension, CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%), Placebo Sterile Otic Suspension; Drug
Lead sponsor: Par Pharmaceutical, Inc.; Industry
Eligibility: 6 Months to 12 Years
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 23
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 17 more

Conditions: Cutaneous Melanoma, Stage II
Interventions: Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin; Procedure
Lead sponsor: Melanoma and Skin Cancer Trials Limited; Other
Eligibility: 18 Years and older
Enrollment: 2,998 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2034
U.S. locations: 128
States / cities: Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 99 more

Conditions: Contraception, Ovulation
Interventions: Ethinyl Estradiol, Norethindrone acetate, ferrous fumarate, Norethindrone; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cerebral Palsy, Neurological Conditions, Mental Retardation, Sialorrhea
Interventions: Oral Glycopyrrolate Liquid; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 3 Years to 18 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 7
States / cities: Lakewood, Colorado • Atlanta, Georgia • Bayside, New York + 4 more

Conditions: Bronchiolitis Obliterans Syndrome, Chronic Lung Allograft Dysfunction, Lung Transplantation
Interventions: LAM-001, Placebo; Drug
Lead sponsor: Steven Hays, MD; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Small Lymphocytic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma
Interventions: Alvocidib Hydrochloride, Cyclophosphamide, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study, Rituximab; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Breast Cancer
Interventions: Docetaxel, Pertuzumab, Trastuzumab emtansine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Charlotte, North Carolina • Houston, Texas

Conditions: Condylomata Acuminata, Papillomavirus Infections, Skin Diseases, Viral, Skin Diseases, Infectious, Skin Diseases, Sexually Transmitted Diseases, Viral, Sexually Transmitted Diseases, Warts
Interventions: VP-102 and applicator, Placebo; Combination Product
Lead sponsor: Verrica Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Plainfield, Indiana • Baton Rouge, Louisiana • Clarkston, Michigan + 1 more

Search by objective public record fields.

A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's Disease

Partial Breast Irradiation (PBI) Using 40 Gy for Select Patients With Early Invasive or Noninvasive Breast Cancer

Hyaluronic Acid Filler for Dorsal Finger Volume Loss

Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform

Evaluating a Novel Method of EEG Evoked Response Potential Analysis in Concussion Assessment, Young Adults and Adults

HIV Screening Take-up: Evaluating Incentives and Opt-out Strategies

Targeting Individual Alpha Frequencies to Enhance Perceptual Timing

Neural Effects of Intravenous N,N-dimethyltryptamine (DMT)

Early Onset and Familial Gastric Cancer Registry

Cilostazol After Lower Extremity Arterial Revascularization Trial

ERr 731® Formulation Evaluation

Study of Ataluren in ≥2 to <5 Year-Old Male Participants With Duchenne Muscular Dystrophy

Does Testosterone Therapy Improve Patient-Reported Outcomes in Age-Related Testosterone Deficient Patients Undergoing Total Hip Replacement: A Randomized-Controlled Trial

Community Activation for Prevention (CAPs): A Study of Community Gardening

The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes

Connecting Youth and Young Adults to Optimize ART Adherence: YouTHrive Efficacy Trial

Bioequivalence of Two Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspensions in Otitis Media in Children With Tympanostomy Tubes

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

Ovulation Incidence in Oral Contraceptive Users

Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions

LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.

Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer

A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts